Arthur S. Leonard

Array ( [id] => 17982883 [patent_doc_number] => 20220348919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => HYBRID NUCLEIC ACID MOLECULES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/742724 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17742724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17930126 [patent_doc_number] => 20220325251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ASSAY AND MEDICAMENT [patent_app_type] => utility [patent_app_number] => 17/725982 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19234067 [patent_doc_number] => 20240191259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS TO ACCEPTOR CELLS [patent_app_type] => utility [patent_app_number] => 18/554139 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216257 [patent_doc_number] => 20240180961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => PLURIPOTENT STEM CELL-DERIVED HEMATOPOIETIC LINEAGES [patent_app_type] => utility [patent_app_number] => 18/284577 [patent_app_country] => US [patent_app_date] => 2022-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -119 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18284577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19702725 [patent_doc_number] => 12196744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Humanized mouse models for assessing immune cell therapy [patent_app_type] => utility [patent_app_number] => 17/705037 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 27 [patent_no_of_words] => 20139 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720441 [patent_doc_number] => 20220213161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS [patent_app_type] => utility [patent_app_number] => 17/700991 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17700991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19203151 [patent_doc_number] => 20240175050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => METHODS AND MATERIALS FOR TREATING PROPIONIC ACIDEMIA [patent_app_type] => utility [patent_app_number] => 18/282645 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828555 [patent_doc_number] => 20220265859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => MRNA TARGETING MOLECULE COMPRISING N-ACETYLGALACTOSAMINE BINDING POLYPEPTIDE AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 17/693173 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300503 [patent_doc_number] => 20240229072 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => VIRAL VECTOR-BASED GENE THERAPY FOR OCULAR CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/547348 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19113095 [patent_doc_number] => 20240124845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => SKELETAL STEM CELL ISOLATION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/547438 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300503 [patent_doc_number] => 20240229072 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => VIRAL VECTOR-BASED GENE THERAPY FOR OCULAR CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/547348 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003531 [patent_doc_number] => 20220362297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY [patent_app_type] => utility [patent_app_number] => 17/674378 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64277 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096386 [patent_doc_number] => 20240115613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => COMPOSITION FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE [patent_app_type] => utility [patent_app_number] => 18/275875 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17579112 [patent_doc_number] => 20220135967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => TUNABLE ENDOGENOUS PROTEIN DEGRADATION [patent_app_type] => utility [patent_app_number] => 17/580190 [patent_app_country] => US [patent_app_date] => 2022-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17580190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034445 [patent_doc_number] => 20240084260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHOD FOR CULTURING HUMAN HEPATIC PARENCHYMAL CELL, CULTURED HUMAN HEPATIC PARENCHYMAL CELL, CULTURE MEDIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CULTURE SUPERNATANT OF HUMAN HEPATIC NONPARENCHYMAL CELL [patent_app_type] => utility [patent_app_number] => 18/271715 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986418 [patent_doc_number] => 20240058387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => CULTURE MEDIUM COMPOSITION FOR AMPLIFYING AND MAINTAINING SELF-RENEWAL CAPACITY AND DIFFERENTIATION POTENTIAL OF HSCS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/270181 [patent_app_country] => US [patent_app_date] => 2021-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18824422 [patent_doc_number] => 11839686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-12 [patent_title] => Lipid formulations with viral immunogens [patent_app_type] => utility [patent_app_number] => 17/560052 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 21 [patent_no_of_words] => 15119 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 904 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561577 [patent_doc_number] => 20220125726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => METHODS OF MAKING LIPID FORMULATIONS WITH IMMUNOGENS [patent_app_type] => utility [patent_app_number] => 17/560116 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18412007 [patent_doc_number] => 11666534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Methods of administering lipid formulations with viral immunogens [patent_app_type] => utility [patent_app_number] => 17/560138 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 21 [patent_no_of_words] => 14958 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18699981 [patent_doc_number] => 11786467 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Lipid formulations with immunogens [patent_app_type] => utility [patent_app_number] => 17/560019 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 21 [patent_no_of_words] => 15132 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560019 [rel_patent_id] =>[rel_patent_doc_number] =>)